Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year Period End

31 December 2019

Interim Results Announcement

11 September 2019

Half Year Period End

30 June 2019

Final Dividend Payment

14 June 2019

Annual General Meeting

5 June 2019

Preliminary Results Announcement

13 March 2019
View Full Calendar

Financial Reports

2018 Interim Report

September 2018

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports


Acquisition of Sealantis

Advanced Medical Solutions Group plc today announces it has acquired Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform.... Read More

Jefferies 2018 London Healthcare Conference – November 14-15 2018

AMS will attend the Jefferies 2018 London Healthcare Conference on the 14 November 2018 in London. Now in its ninth year,... Read More

View More News

Latest Financial Highlights


This has been another good year for the Group and we continue to progress as a leading, international provider of high quality, high value, innovative and technologically advanced products for the surgical and advanced woundcare markets .

Our revenues increased 6% to £102.6 million (2017: £96.9 million), representing growth of 7% on a constant currency basis, our adjusted profit before tax increased by 14% to £28.9 million (2017: £25.4 million) and our profit before tax increased by 32% to £28.4 million (2017: £25.3 million). The continued strong cash generation of the business has resulted in the Group ending the year with net cash of £76.4 million (2017: £62.5 million).

Branded Business Unit sales increased strongly by 12% to £62.1 million and by 13% at constant currency, underlining the potential for our products in the global surgical market, with LiquiBand® contributing £31.7 million of sales at 22% growth, or 24% at constant currency. We extended our future addressable market by adding the Sealantis portfolio to our range.

We strengthened our product portfolio in both Business Units with four key launches in Q4: LiquiBand® Fix 8™ Open (EU), LiquiBand® Exceed Mini (US), silver post-operative dressing (US) and antimicrobial PHMB foam dressing (US).

Given the changing market dynamics, particularly in woundcare and the regulatory environment, we continue to evolve our organisation and strategy to maximise value and efficiency for the Group. In 2018 our strategy has evolved to allow increased focus on our four key strategic pillars of Growth, Innovation, Operational Excellence and Culture and going into 2019, we made some minor adjustments within the Business Units to better manage our different surgical and advanced woundcare opportunities and optimise the Group’s routes to market. We are pleased with the progress we have made and are well positioned to drive continued growth for the future.